MCID: NNL004
MIFTS: 51

Nonalcoholic Fatty Liver Disease

Categories: Metabolic diseases, Liver diseases

Aliases & Classifications for Nonalcoholic Fatty Liver Disease

MalaCards integrated aliases for Nonalcoholic Fatty Liver Disease:

Name: Nonalcoholic Fatty Liver Disease 12 25 37
Non-Alcoholic Fatty Liver Disease 12 25 73
Nonalcoholic Steatohepatitis 25 73
Fatty Liver 25 73
Susceptibility to Nonalcoholic Fatty Liver Disease 6
Non-Alcoholic Steatohepatitis 25
Fatty Degeneration 73
Steatohepatitis 73
Steatosis 25
Nafld 25
Nash 25

Classifications:



External Ids:

Disease Ontology 12 DOID:0080208
KEGG 37 H01333

Summaries for Nonalcoholic Fatty Liver Disease

Genetics Home Reference : 25 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.

MalaCards based summary : Nonalcoholic Fatty Liver Disease, also known as non-alcoholic fatty liver disease, is related to psoriasis and hepatocellular carcinoma. An important gene associated with Nonalcoholic Fatty Liver Disease is MIR122 (MicroRNA 122
In liver, miR-122 regulates several targets affecting lipid homeostasis, including fatty acid synthase, 3-hydroxy-3-methyl-glutarylcoenzyme A reductase and their transcriptional activators, the sterol-response-element binding protein-1c and 2. Therefore, miR-122 downregulation may have a significant role in the pathogenesis of the disease.), and among its related pathways/superpathways are Non-alcoholic fatty liver disease (NAFLD) and Glycerolipid metabolism. The drugs Amlodipine and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and endothelial.

Disease Ontology : 12 A fatty liver disease characterized by the storing of excess fat in liver cells which is is not caused by heavy alcohol use.

Related Diseases for Nonalcoholic Fatty Liver Disease

Diseases in the Nonalcoholic Fatty Liver Disease family:

Fatty Liver Disease, Nonalcoholic 1 Fatty Liver Disease, Nonalcoholic 2

Diseases related to Nonalcoholic Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Related Disease Score Top Affiliating Genes
1 psoriasis 30.1 MIR122 MIR22 MIR31 MIRLET7E
2 hepatocellular carcinoma 29.8 MIR122 MIR22 MIR26A1 MIR27A MIR30A MIR31
3 breast cancer 28.9 MIR10B MIR122 MIR22 MIR27A MIR29C MIR31
4 visceral steatosis 12.1
5 fatty liver disease 12.0
6 fatty liver disease, nonalcoholic 1 11.6
7 liver disease 11.3
8 ovarian serous carcinoma 10.8 MIR10B MIR27A
9 hepatitis 10.8
10 diabetes mellitus, noninsulin-dependent 10.7
11 nonalcoholic steatohepatitis 10.7
12 thyroid cancer, nonmedullary, 1 10.6 MIR26A1 MIR29C MIR34A
13 kidney cancer 10.5 MIR122 MIR27A MIR29C MIR378A
14 primary biliary cirrhosis 10.5 MIR122 MIR30D MIR451A
15 diabetes mellitus 10.5
16 leiomyoma, uterine 10.5 MIR29C MIR30A MIR34A MIR451A MIRLET7C
17 muscular dystrophy, duchenne type 10.4 MIR22 MIR29C MIR30D MIR34A MIR95
18 oral squamous cell carcinoma 10.4 MIR122 MIR27A MIR27B MIR30D MIR31 MIR34A
19 leukemia, chronic lymphocytic 10.4 MIR10B MIR29C MIR30D MIR34A
20 hepatitis c 10.3
21 sleep apnea 10.3
22 apnea, obstructive sleep 10.3
23 arteries, anomalies of 10.3
24 aging 10.3
25 coronary artery anomaly 10.3
26 polycystic ovary syndrome 10.3
27 portal hypertension 10.2
28 hyperuricemia 10.2
29 hepatitis b 10.2
30 hypothyroidism 10.2
31 adenoma 10.2
32 squamous cell carcinoma, head and neck 10.1 MIR122 MIR22 MIR29C MIR31 MIRLET7D MIRLET7E
33 morbid obesity 10.1
34 hemosiderosis 10.1
35 endotheliitis 10.1
36 leukemia, acute lymphoblastic 10.1 MIR22 MIR27A MIR27B MIR451A MIRLET7C MIRLET7E
37 rheumatoid arthritis 10.0
38 insulin-like growth factor i 10.0
39 helicobacter pylori infection 10.0
40 hepatitis c virus 10.0
41 arthritis 10.0
42 chronic kidney failure 10.0
43 colorectal adenoma 10.0
44 vascular disease 10.0
45 viral hepatitis 10.0
46 thrombophilia 10.0
47 pancreas disease 10.0
48 pancreatitis 10.0
49 kidney disease 10.0
50 thyroiditis 10.0

Graphical network of the top 20 diseases related to Nonalcoholic Fatty Liver Disease:



Diseases related to Nonalcoholic Fatty Liver Disease

Symptoms & Phenotypes for Nonalcoholic Fatty Liver Disease

Drugs & Therapeutics for Nonalcoholic Fatty Liver Disease

Drugs for Nonalcoholic Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 310)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amlodipine Approved Phase 4 88150-42-9 2162
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
5
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
6
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
7
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
8
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
9
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 23994
10
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
11
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
12
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
13
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
14
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
15
Insulin Aspart Approved Phase 4 116094-23-6 16132418
16
Insulin Detemir Approved Phase 4 169148-63-4 5311023
17
Gliclazide Approved Phase 4 21187-98-4 3475
18
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
19
Rifampicin Approved Phase 4,Phase 1 13292-46-1 5458213 5381226
20
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
21
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
22
Empagliflozin Approved Phase 4,Not Applicable 864070-44-0
23
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173
24
Glimepiride Approved Phase 4 93479-97-1 3476
25
Saxagliptin Approved Phase 4 361442-04-8 11243969
26
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
27
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-02-9 14985
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 59-30-3 6037
29
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3 66-72-8 1050
30
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3 65-23-6 1054
31
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-14-6 5280793
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
33
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
34 tannic acid Approved, Nutraceutical Phase 4,Phase 3
35
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 6221 5280795
36
Ginseng Approved, Investigational, Nutraceutical Phase 4,Not Applicable 50647-08-0
37
2,4-thiazolidinedione Investigational Phase 4,Phase 2 2295-31-0
38 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Tocopherols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Tocotrienols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2
42 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
43 Angiotensin-Converting Enzyme Inhibitors Phase 4
44 Angiotensinogen Phase 4,Phase 3,Phase 2
45 Antihypertensive Agents Phase 4,Phase 3,Phase 2
46 calcium channel blockers Phase 4
47 Calcium, Dietary Phase 4,Phase 2,Not Applicable
48 HIV Protease Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
49
protease inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
50 Vasodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 625)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
4 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
5 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
6 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
7 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
8 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
9 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
10 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
11 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
12 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
13 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
14 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
15 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
16 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
17 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
18 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
19 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
20 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
21 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
22 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
23 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
24 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
25 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
26 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
27 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Recruiting NCT02303730 Phase 4 Exenatide;insulin glargine
28 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
29 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4 Metformin;Placebo
30 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Recruiting NCT02637973 Phase 4 Empagliflozin;Placebo
31 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin
32 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
33 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease Enrolling by invitation NCT03222206 Phase 4 Salsalate
34 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Enrolling by invitation NCT02210715 Phase 4 Isentress.
35 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Not yet recruiting NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
36 Silymarin in NAFLD Not yet recruiting NCT02973295 Phase 4 Silymarin
37 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Not yet recruiting NCT03198572 Phase 4 Placebo;Berberine
38 High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes Not yet recruiting NCT03403556 Phase 4 Rosuvamibe;Monorova
39 Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) Terminated NCT00736385 Phase 4 Glucophage (Metformin);Placebo
40 Fatty Liver Study in Patients With Type II Diabetes Terminated NCT02365233 Phase 4 DPP4 inhibitor;Pioglitazone;Lantus insulin
41 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
42 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
43 Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI Withdrawn NCT02263677 Phase 4 Sitagliptin
44 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
45 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3
46 Metformin in Non-Alcoholic Fatty Liver Disease Unknown status NCT00303537 Phase 2, Phase 3 metformin
47 A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease Unknown status NCT02265276 Phase 3 Saroglitazar;Pioglitazone
48 The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver Unknown status NCT02530138 Phase 2, Phase 3
49 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3 Vitamin D
50 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol

Search NIH Clinical Center for Nonalcoholic Fatty Liver Disease

Genetic Tests for Nonalcoholic Fatty Liver Disease

Anatomical Context for Nonalcoholic Fatty Liver Disease

MalaCards organs/tissues related to Nonalcoholic Fatty Liver Disease:

41
Liver, Testes, Endothelial, Kidney, Ovary, Heart, Bone

Publications for Nonalcoholic Fatty Liver Disease

Articles related to Nonalcoholic Fatty Liver Disease:

(show top 50) (show all 1515)
# Title Authors Year
1
Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. ( 29429367 )
2018
2
Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease. ( 29934919 )
2018
3
Chicory (Cichorium intybus L.) polysaccharides attenuate high-fat diet induced non-alcoholic fatty liver disease via AMPK activation. ( 29964102 )
2018
4
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( 29946793 )
2018
5
Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns. ( 29963461 )
2018
6
Role of genetic and metabolism in non-alcoholic fatty liver disease. ( 29442484 )
2018
7
Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. ( 29951367 )
2018
8
PNPLA3: A Determinant of Response to Low-Fructose Diet in Nonalcoholic Fatty Liver Disease. ( 29452087 )
2018
9
A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis. ( 29942422 )
2018
10
Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. ( 29235054 )
2018
11
Urea cycle dysregulation in non-alcoholic fatty liver disease. ( 29981428 )
2018
12
Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. ( 29438460 )
2018
13
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. ( 29427497 )
2018
14
Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. ( 29434074 )
2018
15
Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. ( 29969922 )
2018
16
Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. ( 29428103 )
2018
17
The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. ( 29956209 )
2018
18
Normal serum alanine aminotransferase and non-alcoholic fatty liver disease among Korean adolescents: a cross-sectional study using data from KNHANES 2010-2015. ( 29976192 )
2018
19
Correction: Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. ( 29944727 )
2018
20
Changes in inflammatory factors and prognosis of patients complicated with non-alcoholic fatty liver disease undergoing coronary artery bypass grafting. ( 29434690 )
2018
21
Future therapy for non-alcoholic fatty liver disease. ( 29427492 )
2018
22
Evaluation of nonalcoholic fatty liver disease using magnetic resonance in obese children and adolescents. ( 29438686 )
2018
23
Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2. ( 29449533 )
2018
24
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. ( 29368124 )
2018
25
Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. ( 29931231 )
2018
26
Huperzine A attenuates nonalcoholic fatty liver disease by regulating hepatocyte senescence and apoptosis: an in vitro study. ( 29967757 )
2018
27
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. ( 29404514 )
2018
28
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model. ( 29975946 )
2018
29
Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. ( 29956688 )
2018
30
Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in the Serum of Patients with Non-alcoholic Fatty Liver Disease. ( 29970524 )
2018
31
Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study. ( 29415050 )
2018
32
Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance. ( 29968484 )
2018
33
Relationship between diverticulosis and nonalcoholic fatty liver disease in elderly patients. ( 29432700 )
2018
34
Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. ( 29441049 )
2018
35
A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. ( 29769552 )
2018
36
<i>Helicobacter pylori</i> Infection Is Not Associated with Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study in China. ( 29445363 )
2018
37
Association of Lipoprotein-Associated Phospholipase A2 with the Prevalence of Nonalcoholic Fatty Liver Disease: A Result from the APAC Study. ( 29973631 )
2018
38
Effects of liraglutide, metformin, and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. ( 29957886 )
2018
39
Nonalcoholic Fatty Liver Disease in University Rugby Football Players. ( 29973915 )
2018
40
Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease. ( 29955036 )
2018
41
Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. ( 29948305 )
2018
42
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. ( 29971527 )
2018
43
Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis. ( 29451179 )
2018
44
Developmental Origins of Nonalcoholic Fatty Liver Disease (NAFLD). ( 29956192 )
2018
45
Association between nonalcoholic fatty liver disease and colorectal Tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. ( 29935236 )
2018
46
Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal. ( 29980170 )
2018
47
Hepatopulmonary syndrome caused by hypothalamic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma: a case report. ( 29609450 )
2018
48
Non-Invasive Diagnosis of Nonalcoholic Fatty Liver Disease. ( 29937542 )
2018
49
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough. ( 29427494 )
2018
50
NON-ALCOHOLIC FATTY LIVER DISEASE AND RISK OF DIABETES: A PROSPECTIVE STUDY IN CHINA. ( 29975579 )
2018

Variations for Nonalcoholic Fatty Liver Disease

ClinVar genetic disease variations for Nonalcoholic Fatty Liver Disease:

6
(show top 50) (show all 92)
# Gene Variation Type Significance SNP ID Assembly Location
1 PNPLA3 NM_025225.2(PNPLA3): c.-112A> T single nucleotide variant Likely benign rs531789428 GRCh38 Chromosome 22, 43923800: 43923800
2 PNPLA3 NM_025225.2(PNPLA3): c.-112A> T single nucleotide variant Likely benign rs531789428 GRCh37 Chromosome 22, 44319680: 44319680
3 PNPLA3 NM_025225.2(PNPLA3): c.-111G> A single nucleotide variant Likely benign rs548897706 GRCh38 Chromosome 22, 43923801: 43923801
4 PNPLA3 NM_025225.2(PNPLA3): c.-111G> A single nucleotide variant Likely benign rs548897706 GRCh37 Chromosome 22, 44319681: 44319681
5 PNPLA3 NM_025225.2(PNPLA3): c.-44C> G single nucleotide variant Uncertain significance rs773713393 GRCh38 Chromosome 22, 43923868: 43923868
6 PNPLA3 NM_025225.2(PNPLA3): c.-44C> G single nucleotide variant Uncertain significance rs773713393 GRCh37 Chromosome 22, 44319748: 44319748
7 PNPLA3 NM_025225.2(PNPLA3): c.972C> T (p.Leu324=) single nucleotide variant Likely benign rs116679026 GRCh37 Chromosome 22, 44333145: 44333145
8 PNPLA3 NM_025225.2(PNPLA3): c.972C> T (p.Leu324=) single nucleotide variant Likely benign rs116679026 GRCh38 Chromosome 22, 43937265: 43937265
9 PNPLA3 NM_025225.2(PNPLA3): c.980-15A> C single nucleotide variant Likely benign rs144872932 GRCh37 Chromosome 22, 44335858: 44335858
10 PNPLA3 NM_025225.2(PNPLA3): c.980-15A> C single nucleotide variant Likely benign rs144872932 GRCh38 Chromosome 22, 43939978: 43939978
11 PNPLA3 NM_025225.2(PNPLA3): c.992A> G (p.Glu331Gly) single nucleotide variant Likely benign rs144233415 GRCh37 Chromosome 22, 44335885: 44335885
12 PNPLA3 NM_025225.2(PNPLA3): c.992A> G (p.Glu331Gly) single nucleotide variant Likely benign rs144233415 GRCh38 Chromosome 22, 43940005: 43940005
13 PNPLA3 NM_025225.2(PNPLA3): c.1209C> T (p.Pro403=) single nucleotide variant Uncertain significance rs184910573 GRCh37 Chromosome 22, 44340667: 44340667
14 PNPLA3 NM_025225.2(PNPLA3): c.1209C> T (p.Pro403=) single nucleotide variant Uncertain significance rs184910573 GRCh38 Chromosome 22, 43944787: 43944787
15 PNPLA3 NM_025225.2(PNPLA3): c.1340G> A (p.Arg447Gln) single nucleotide variant Uncertain significance rs147289545 GRCh37 Chromosome 22, 44342156: 44342156
16 PNPLA3 NM_025225.2(PNPLA3): c.1340G> A (p.Arg447Gln) single nucleotide variant Uncertain significance rs147289545 GRCh38 Chromosome 22, 43946276: 43946276
17 PNPLA3 NM_025225.2(PNPLA3): c.1358G> T (p.Ser453Ile) single nucleotide variant Likely benign rs6006460 GRCh37 Chromosome 22, 44342174: 44342174
18 PNPLA3 NM_025225.2(PNPLA3): c.1358G> T (p.Ser453Ile) single nucleotide variant Likely benign rs6006460 GRCh38 Chromosome 22, 43946294: 43946294
19 PNPLA3 NM_025225.2(PNPLA3): c.*19T> G single nucleotide variant Uncertain significance rs569255289 GRCh37 Chromosome 22, 44342281: 44342281
20 PNPLA3 NM_025225.2(PNPLA3): c.*19T> G single nucleotide variant Uncertain significance rs569255289 GRCh38 Chromosome 22, 43946401: 43946401
21 PNPLA3 NM_025225.2(PNPLA3): c.*71T> G single nucleotide variant Uncertain significance rs886057601 GRCh37 Chromosome 22, 44342333: 44342333
22 PNPLA3 NM_025225.2(PNPLA3): c.*71T> G single nucleotide variant Uncertain significance rs886057601 GRCh38 Chromosome 22, 43946453: 43946453
23 PNPLA3 NM_025225.2(PNPLA3): c.*691_*692dupAA duplication Likely benign rs397716964 GRCh37 Chromosome 22, 44342953: 44342954
24 PNPLA3 NM_025225.2(PNPLA3): c.*691_*692dupAA duplication Likely benign rs397716964 GRCh38 Chromosome 22, 43947073: 43947074
25 PNPLA3 NM_025225.2(PNPLA3): c.*889A> G single nucleotide variant Likely benign rs1810508 GRCh38 Chromosome 22, 43947271: 43947271
26 PNPLA3 NM_025225.2(PNPLA3): c.*889A> G single nucleotide variant Likely benign rs1810508 GRCh37 Chromosome 22, 44343151: 44343151
27 PNPLA3 NM_025225.2(PNPLA3): c.*988_*989dupAA duplication Likely benign rs397775086 GRCh38 Chromosome 22, 43947370: 43947371
28 PNPLA3 NM_025225.2(PNPLA3): c.*988_*989dupAA duplication Likely benign rs397775086 GRCh37 Chromosome 22, 44343250: 44343251
29 PNPLA3 NM_025225.2(PNPLA3): c.*1090A> G single nucleotide variant Likely benign rs9626058 GRCh38 Chromosome 22, 43947472: 43947472
30 PNPLA3 NM_025225.2(PNPLA3): c.*1090A> G single nucleotide variant Likely benign rs9626058 GRCh37 Chromosome 22, 44343352: 44343352
31 PNPLA3 NM_025225.2(PNPLA3): c.-168C> A single nucleotide variant Likely benign rs140746182 GRCh38 Chromosome 22, 43923744: 43923744
32 PNPLA3 NM_025225.2(PNPLA3): c.-168C> A single nucleotide variant Likely benign rs140746182 GRCh37 Chromosome 22, 44319624: 44319624
33 PNPLA3 NM_025225.2(PNPLA3): c.187+12G> A single nucleotide variant Likely benign rs116795637 GRCh38 Chromosome 22, 43924110: 43924110
34 PNPLA3 NM_025225.2(PNPLA3): c.187+12G> A single nucleotide variant Likely benign rs116795637 GRCh37 Chromosome 22, 44319990: 44319990
35 PNPLA3 NM_025225.2(PNPLA3): c.216T> C (p.Leu72=) single nucleotide variant Uncertain significance rs147412464 GRCh38 Chromosome 22, 43926963: 43926963
36 PNPLA3 NM_025225.2(PNPLA3): c.216T> C (p.Leu72=) single nucleotide variant Uncertain significance rs147412464 GRCh37 Chromosome 22, 44322843: 44322843
37 PNPLA3 NM_025225.2(PNPLA3): c.309G> A (p.Pro103=) single nucleotide variant Likely benign rs79118505 GRCh38 Chromosome 22, 43927056: 43927056
38 PNPLA3 NM_025225.2(PNPLA3): c.309G> A (p.Pro103=) single nucleotide variant Likely benign rs79118505 GRCh37 Chromosome 22, 44322936: 44322936
39 PNPLA3 NM_025225.2(PNPLA3): c.646A> C (p.Thr216Pro) single nucleotide variant Uncertain significance rs35726887 GRCh37 Chromosome 22, 44328917: 44328917
40 PNPLA3 NM_025225.2(PNPLA3): c.646A> C (p.Thr216Pro) single nucleotide variant Uncertain significance rs35726887 GRCh38 Chromosome 22, 43933037: 43933037
41 PNPLA3 NM_025225.2(PNPLA3): c.659A> G (p.Tyr220Cys) single nucleotide variant Uncertain significance rs143392071 GRCh37 Chromosome 22, 44328930: 44328930
42 PNPLA3 NM_025225.2(PNPLA3): c.659A> G (p.Tyr220Cys) single nucleotide variant Uncertain significance rs143392071 GRCh38 Chromosome 22, 43933050: 43933050
43 PNPLA3 NM_025225.2(PNPLA3): c.980-14A> C single nucleotide variant Uncertain significance rs781212740 GRCh37 Chromosome 22, 44335859: 44335859
44 PNPLA3 NM_025225.2(PNPLA3): c.980-14A> C single nucleotide variant Uncertain significance rs781212740 GRCh38 Chromosome 22, 43939979: 43939979
45 PNPLA3 NM_025225.2(PNPLA3): c.1112+14G> A single nucleotide variant Uncertain significance rs138736228 GRCh37 Chromosome 22, 44336019: 44336019
46 PNPLA3 NM_025225.2(PNPLA3): c.1112+14G> A single nucleotide variant Uncertain significance rs138736228 GRCh38 Chromosome 22, 43940139: 43940139
47 PNPLA3 NM_025225.2(PNPLA3): c.1300A> G (p.Lys434Glu) single nucleotide variant Likely benign rs2294918 GRCh37 Chromosome 22, 44342116: 44342116
48 PNPLA3 NM_025225.2(PNPLA3): c.1300A> G (p.Lys434Glu) single nucleotide variant Likely benign rs2294918 GRCh38 Chromosome 22, 43946236: 43946236
49 PNPLA3 NM_025225.2(PNPLA3): c.1419C> T (p.Pro473=) single nucleotide variant Uncertain significance rs376208148 GRCh37 Chromosome 22, 44342235: 44342235
50 PNPLA3 NM_025225.2(PNPLA3): c.1419C> T (p.Pro473=) single nucleotide variant Uncertain significance rs376208148 GRCh38 Chromosome 22, 43946355: 43946355

Expression for Nonalcoholic Fatty Liver Disease

Search GEO for disease gene expression data for Nonalcoholic Fatty Liver Disease.

Pathways for Nonalcoholic Fatty Liver Disease

Pathways related to Nonalcoholic Fatty Liver Disease according to KEGG:

37
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease (NAFLD) hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.94 MIR10B MIR122 MIR26A1 MIR27A MIR27B MIR29C
2 11.03 MIR27A MIR27B MIRLET7D
3 10.89 MIR30D MIR429
4 10.7 MIR29C MIRLET7C MIRLET7D MIRLET7E

GO Terms for Nonalcoholic Fatty Liver Disease

Cellular components related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 MIR10B MIR122 MIR22 MIR26A1 MIR27A MIR27B

Biological processes related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.54 MIR26A1 MIR29C
2 miRNA mediated inhibition of translation GO:0035278 9.54 MIR27A MIR27B MIR31
3 positive regulation of blood vessel endothelial cell migration GO:0043536 9.52 MIR30A MIR31
4 negative regulation of vascular endothelial cell proliferation GO:1905563 9.51 MIR29C MIR34A
5 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.49 MIR26A1 MIR29C
6 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.48 MIR26A1 MIR451A
7 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.46 MIR10B MIR27B
8 positive regulation of angiogenesis GO:0045766 9.46 MIR27B MIR30A MIR31 MIR378A
9 positive regulation of cellular senescence GO:2000774 9.43 MIR22 MIR34A
10 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.43 MIR22 MIR26A1 MIR29C
11 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.4 MIR27A MIR27B
12 gene silencing by miRNA GO:0035195 9.4 MIR10B MIR22 MIR26A1 MIR27A MIR27B MIR29C
13 positive regulation of smooth muscle cell differentiation GO:0051152 9.32 MIR22 MIR34A
14 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.13 MIR10B MIR27B MIR31

Molecular functions related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.4 MIR10B MIR22 MIR26A1 MIR27A MIR27B MIR29C

Sources for Nonalcoholic Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....